| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d202e9e866984fe229f6facc38f1d740 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D239-26
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D215-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-22
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D215-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D239-26
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-47
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-505 |
| filingDate |
2005-10-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_23322a835b8d2c680150860052c19e7c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b6d340ee2b470d72570c6c42e8362d7b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4ff1485e250ee388f45eba408efb1b07
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ac0f7da56081e302ec6d017d5c3bd038
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_af5320f04870a0d68f442315e3504e80 |
| publicationDate |
2006-05-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
CA-2585210-A1 |
| titleOfInvention |
Pyrimidine and quinoline potentiators of metabotropic glutamate receptors |
| abstract |
The present invention is directed to compounds which are potentiators of metabotropic glutamate receptors, including the mGluR2 receptor, and which are useful in the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which metabotropic glutamate receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which metabotropic glutamate receptors are involved. |
| priorityDate |
2004-10-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |